Galderma and Sofregen to Develop Silk-based Biostimulator Fillers

Galderma and Sofregen Medical have announced a co-development and option-to-acquire agreement for Sofregen’s Silk Voice.

Silk
Courtesy of Sofregen Medical

Galderma and Sofregen Medical have announced a co-development and option-to-acquire agreement for Sofregen's Silk Voice, as well as assets associated with its aesthetic business.

Sofregen Medical is a medical device company pioneering the use of silk protein for tissue building and regeneration. This option will grant Galderma all rights to the products being co-developed, as well as ownership of Sofregen’s silk technology platform in the aesthetic and dermatological field.

Galderma and Sofregen plan to launch development programs for all products soon, with both companies looking to get the collaboration underway and bring the products to market as quickly as possible.

"Galderma is a world leader in dermatology, with decades of experience in delivering cutting edge innovation in facial aesthetics and we are thrilled to have them as a partner. This agreement highlights Sofregen’s dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space,” said Jonathan T. Hartmann, CEO of Sofregen.


More in News